HXBM (Helix Biomedix) ROCE %: -192.54% (As of Sep. 2012)


What is Helix Biomedix ROCE %?

Helix Biomedix HXBM ROCE % is -192.54% as of Sep. 2012.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Helix Biomedix's annualized ROCE % for the quarter that ended in Sep. 2012 was -192.54%.

Helix Biomedix  (OTCPK:HXBM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Helix Biomedix ROCE % Related Terms

Helix Biomedix ROCE % Historical Data

* Premium members only.

The historical data trend for Helix Biomedix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix Biomedix ROCE % Chart

Helix Biomedix Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -157.38 -223.60 -191.15 -87.20 -64.33

Helix Biomedix Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -69.64 -77.02 -85.20 -104.08 -192.54

Helix Biomedix ROCE % Calculation

Helix Biomedix's annualized ROCE % for the fiscal year that ended in Dec. 2011 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2011 )  (A: Dec. 2010 )(A: Dec. 2011 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2011 )  (A: Dec. 2010 )(A: Dec. 2011 )
=-2.404/( ( (5.228 - 0.318) + (2.975 - 0.411) )/ 2 )
=-2.404/( (4.91+2.564)/ 2 )
=-2.404/3.737
=-64.33 %

Helix Biomedix's ROCE % of for the quarter that ended in Sep. 2012 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2012 )  (Q: Jun. 2012 )(Q: Sep. 2012 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2012 )  (Q: Jun. 2012 )(Q: Sep. 2012 )
=-2.992/( ( (2.233 - 0.307) + (1.702 - 0.52) )/ 2 )
=-2.992/( ( 1.926 + 1.182 )/ 2 )
=-2.992/1.554
=-192.54 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2012) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -192.54% mean?
Helix Biomedix (HXBM) has a ROCE % of -192.54% as of Sep. 2012.
Is Helix Biomedix's ROCE % too high?
Helix Biomedix's current ROCE % is -192.54%.
How does Helix Biomedix's ROCE % compare to XBIO and CBLI?
Helix Biomedix's ROCE % of -192.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Helix Biomedix's current ROCE % is -192.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix Biomedix stock overvalued right now?
Helix Biomedix (HXBM) has a current ROCE % of -192.54%. The current ROCE % is -192.54%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Helix Biomedix (HXBM), the current ROCE % is -192.54% as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix Biomedix Business Description

Address 19125 North Creek Parkway, Suite 120, Bothell, WA, USA, 98011
Helix Biomedix Inc is a Delaware-based biopharmaceutical company that focuses on the early-stage development of peptide-based therapeutics for dermatology and skin health. The Company is in the preclinical stage, advancing a rare disease drug program for xeroderma pigmentosum, and plans to seek orphan drug designation before entering clinical development. Leveraging its proprietary peptide technology, Helix BioMedix aims to address unmet needs in rare dermatological conditions and has a history of developing patented bioactive peptides for topical personal care use.